Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UVLOX
- Development stage
- Unknown
- Lead developer
- Percos
- Administration
- Topical
01
Overview
UVLOX is a topical sunscreen gel developed and marketed by Percos. It is formulated to provide broad-spectrum protection against ultraviolet A (UVA) and ultraviolet B (UVB) radiation, as well as blue light emitted from digital screens. The formulation contains encapsulated sunscreen filters (including avobenzone, octinoxate, octocrylene, and titanium dioxide) along with skin-nourishing ingredients like hyaluronic acid, niacinamide, and antioxidants. It is designed to prevent sunburn, skin tanning, hyperpigmentation, and premature skin aging while maintaining a lightweight, non-greasy, and matte finish suitable for all skin types.
- Brand names
- UVLOX
Beyond the preview
Go deeper on UVLOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UVLOX.